Document is current
Any future updates will be listed below
-
Authors
Kobori, Chie
Takagi, Ryo
Yokomizo, Ryo
Yoshihara, Sakie
Mori, Mai
Takahashi, Hiroto
Javaregowda, Palaksha Kanive
Akiyama, Tomohiko
Ko, Minoru S. H.
Kishi, Kazuo
Umezawa, Akihiro
-
Funding
Funding for this research was provided by:
National Center for Child Health and Development
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 29 August 2023
First Online: 8 September 2023
Declarations
:
: The institutional Review Board approved all experiments using human tissues at National Center for Child Health and Development (approval number: 197). We obtained informed consent from all participants or their parents when participants were under 18. Human cells in this study were utilized in full compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects (Ministry of Health, Labor, and Welfare (MHLW), Japan; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan). The derivation and cultivation of human Embryonic Stem Cell lines were performed in full compliance with “the Guidelines for Derivation and Distribution of hESCs (Notifications of MEXT, No. 156 of August 21, 2009; notifications of MEXT, No. 86 of May 20, 2010) and “the Guidelines for Utilization of Human Embryonic Stem Cells (notifications of MEXT, No. 157 of August 21, 2009; notifications of MEXT, No. 87 of May 20, 2010)”. Animal experiments were performed in compliance with the basic guidelines for the conduct of animal experiments in implementing agencies under the jurisdiction of the Ministry of Health, Labour, and Welfare (notifications of MHLW, No. 0220-1 of February 20, 2015). The Institutional Animal Care and Use Committee of the National Center for Child Health and Development approved the protocols of the animal experiments (approval number: A2003-002-C20-M01, title: Research on regenerative medicine and cell medicine using mesenchymal stem cells, iPS cells, and ES cells, and on toxicity testing). This study was carried out in compliance with the ARRIVE guidelines.
: Not applicable.
: AU is a co-researcher with MTI Ltd., Terumo Corp., CellSeed Inc., SEKISUI MEDICAL Ltd., Metcela Inc., PhoenixBio Ltd., Dai Nippon Printing Ltd. AU is a stockholder of TMU Science Ltd., Morikuni Ltd., and Japan Tissue Engineering Ltd. AU is the associate editor of this journal but was not involved in the peer review or decision making of this manuscript. The other authors declare no conflict of interest regarding the work described herein.
